Complement factor C5 deficiency significantly delays the progression of biliary fibrosis in bile duct-ligated mice

Biochemical and Biophysical Research Communications

Volumn 418, Issue 3, 2012, Pages 445-450

  Schmitt, Johannes ^a   Roderfeld, Martin ^b   Sabrane, Karim ^a   Zhang, Pan ^a   Tian, Yinghua ^a   Mertens, Joachim C ^a   Frei, Pascal ^a   Stieger, Bruno ^a,c   Weber, Achim ^a   Müllhaupt, Beat ^a   Roeb, Elke ^b   Geier, Andreas ^a,c,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cholestatic liver disease; Leukocytes; MMP9; Peribiliary infiltration

Indexed keywords

CD45 ANTIGEN; COMPLEMENT COMPONENT C5; GELATINASE; GELATINASE B; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILIARY TRACT FIBROSIS; CELL INFILTRATION; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROGENESIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BILE DUCTS; BIOLOGICAL MARKERS; COMPLEMENT C3; COMPLEMENT C5; DISEASE PROGRESSION; LEUKOCYTES; LIGATION; LIVER CIRRHOSIS, BILIARY; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS;

MURINAE; MUS;

EID: 84857094840     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.036     Document Type: Article

References (40)

1. Sokol R.J., Devereaux M., Dahl R., et al. "Let there be bile" - understanding hepatic injury in cholestasis. J. Pediatr. Gastroenterol. Nutr. 2006, 43(Suppl. 1):S4-S9.
2. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. N. Engl. J. Med. 2005, 353:1261-1273.
3. Tischendorf J.J., Geier A., Trautwein C. Current diagnosis and management of primary sclerosing cholangitis. Liver Transpl. 2008, 14:735-746.
4. Hohenester S., Oude-Elferink R.P., Beuers U. Primary biliary cirrhosis. Semin. Immunopathol. 2009, 31:283-307.
5. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
6. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
7. -/- mice. Hepatology 2010, 51:267-276.
8. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525-531.
9. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3:318-328.
10. Fickert P., Wagner M., Marschall H.U., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
11. Beuers U., Kullak-Ublick G.A., Pusl T., et al. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?. Clin. Rev. Allergy Immunol. 2009, 36:52-61.
12. Qin X., Gao B. The complement system in liver diseases. Cell Mol. Immunol. 2006, 3:333-340.
13. Klos A., Tenner A.J., Johswich K.O., et al. The role of the anaphylatoxins in health and disease. Mol. Immunol. 2009, 46:2753-2766.
14. Ohshio G., Furukawa F., Manabe T., et al. Relationship between secretory IgA, IgA-containing (C3-fixing) circulating immune complexes, and complement components (C3, C4) in patients with obstructive jaundice. Scand. J. Gastroenterol. 1986, 21:151-157.
15. Schlesinger M., Benbassat C., Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol. Res. 1992, 11:98-103.
16. Senaldi G., Donaldson P.T., Magrin S., et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 1989, 97:1430-1434.
17. Gardinali M., Conciato L., Cafaro C., et al. Complement system is not activated in primary biliary cirrhosis. Clin. Immunol. Immunopathol. 1998, 87:297-303.
18. Hirai I., Ishiyama S., Fuse A., et al. Primary sclerosing cholangitis successfully treated by resection of the confluence of the hepatic duct. J. Hepatobiliary Pancreat. Surg. 2001, 8:169-173.
19. Lindgren S., Forsberg B., Eriksson S. Observations during long-term plasma exchange in primary biliary cirrhosis. Scand. J. Gastroenterol. 1985, 20:1124-1126.
20. Li J., Pircher P.C., Schulman I.G., et al. Regulation of complement C3 expression by the bile acid receptor FXR. J. Biol. Chem. 2005, 280:7427-7434.
21. Hillebrandt S., Wasmuth H.E., Weiskirchen R., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat. Genet. 2005, 37:835-843.
22. Halangk J., Sarrazin C., Neumann K., et al. Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. J. Hepatol. 2008, 49:339-345.
23. D. van der Poorten, J. George, Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis, Clin. Liver Dis. 12 (2008) 805-824, ix.
24. Geier A., Zollner G., Dietrich C.G., et al. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. Hepatology 2005, 41:470-477.
25. Roderfeld M., Weiskirchen R., Wagner S., et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J. 2006, 20:444-454.
26. Rath T., Roderfeld M., Halwe J.M., et al. Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand. J. Gastroenterol. 2010, 45:1186-1196.
27. Glaser S.S., Gaudio E., Miller T., et al. Cholangiocyte proliferation and liver fibrosis. Expert. Rev. Mol. Med. 2009, 11:e7.
28. Carvalho E., Liu C., Shivakumar P., et al. Analysis of the biliary transcriptome in experimental biliary atresia. Gastroenterology 2005, 129:713-717.
29. Geier A., Wagner M., Dietrich C.G., et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 2007, 1773:283-308.
30. Georgiev P., Jochum W., Heinrich S., et al. Characterization of time-related changes after experimental bile duct ligation. Br. J. Surg. 2008, 95:646-656.
31. Patsenker E., Popov Y., Stickel F., et al. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135:660-670.
32. Roderfeld M., Geier A., Dietrich C.G., et al. Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver Int. 2006, 26:579-586.
33. Roychowdhury S., McMullen M.R., Pritchard M.T., et al. An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. Hepatology 2009, 49:1326-1334.
34. Diaz-Gil J.J., Garcia-Monzon C., Rua C., et al. The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats. Histol. Histopathol. 2008, 23:583-591.
35. Jonsson J.R., Clouston A.D., Ando Y., et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001, 121:148-155.
36. Rensen S.S., Slaats Y., Driessen A., et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 2009, 50:1809-1817.
37. J.I. Cohen, S. Roychowdhury, M.R. McMullen, et al., Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice, Gastroenterology (2010).
38. Gressner O., Meier U., Hillebrandt S., et al. Gc-globulin concentrations and C5 haplotype-tagging polymorphisms contribute to variations in serum activity of complement factor C5. Clin. Biochem. 2007, 40:771-775.
39. Davin J.C., Gracchi V., Bouts A., et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am. J. Kidney Dis. 2010, 55:708-711.
40. Patel M.R., Worthley S.G., Stebbins A., et al. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. JACC Cardiovasc. Imag. 2010, 3:52-60.